Flavonoids as new regulators of mitochondrial potassium channels: contribution to cardioprotection

Rafał P Kampa1,2, Aleksandra Sęk1,3, Piotr Bednarczyk4

  • 1Laboratory of Intracellular Ion Channels, Nencki Institute of Experimental Biology PAS, Warsaw, Poland.

Abstract

Insights

Flavonoids can protect the heart by activating mitochondrial potassium (mitoK) channels. This review highlights specific flavonoids that modulate mitoK channels for cardioprotection against myocardial infarction.

Area of Science:

  • Cardiovascular Science
  • Mitochondrial Biology
  • Pharmacology

Background:

  • Acute myocardial ischemia causes irreversible heart damage by reducing cardiomyocyte populations.
  • Mitochondrial potassium (mitoK) channels are key regulators of mitochondrial function and cellular metabolism, playing a role in cardioprotection.
  • mitoK channels represent a promising therapeutic target for cardiovascular diseases like myocardial infarction.

Approach:

  • This review focuses on selecting flavonoids with demonstrated cardioprotective properties.
  • The selection criteria emphasize flavonoids that activate mitoK channels.
  • The study provides an overview of mitoK channels and their role in cytoprotective processes.

Key Points:

  • Naringenin, quercetin, morin, theaflavin, baicalein, epigallocatechin gallate, genistein, puerarin, luteolin, and proanthocyanidins are identified as effective mitoK channel modulators.
  • These flavonoids mediate numerous beneficial effects on cardiovascular health.
  • Their activation of mitoK channels contributes to cardioprotective mechanisms.

Conclusions:

  • The pathophysiological significance of mitoK channels in cardiovascular disorders is explored.
  • The impact of various flavonoids on mitoK channels as a therapeutic target is investigated.
  • Flavonoids show potential for preventing cardiovascular diseases through mitoK channel modulation.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.6K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
667
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
681
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
1.4K